Yi-Long Wu

Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute

China

Guangdong Academy of Medical Sciences, Guangdong General Hospital, Guangdong Lung Cancer Institute, Department of Pulmonary Oncology

China

SCHOLARLY PAPERS

9

DOWNLOADS

254

SSRN CITATIONS

4

CROSSREF CITATIONS

0

Scholarly Papers (9)

1.

Nivolumab versus Docetaxel in a Predominantly Chinese Patient Population with Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 078 Randomised Phase 3 Clinical Trial

Number of pages: 31 Posted: 25 Sep 2018
Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Shanghai Jiao Tong University (SJTU), Jilin Cancer Hospital, Tongji University - Department of Medical Oncology, Chinese Academy of Sciences (CAS), The Chinese University of Hong Kong (CUHK), Sun Yat-sen University (SYSU), Guangdong Academy of Medical Sciences, Central South University - Hunan Cancer Hospital, Nanjing Medical University - Jiangsu Institute of Cancer Research, Zhejiang Cancer Hospital, Leningrad Regional Clinical Hospital, Zhejiang University, Zhengzhou University - Henan Cancer Hospital, Sichuan University - West China Hospital, Central South University, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Department of Medical Oncology, Bristol-Myers Squibb, Bristol-Myers Squibb and Fudan University
Downloads 70 (412,507)
Citation 4

Abstract:

Loading...

nivolumab; PD-1 inhibitor; non-small-cell lung cancer; NSCLC; China; docetaxel; immunotherapy

2.

A Phase 1b Study of Savolitinib Plus Gefitinib for Patients with EGFR-Mutated MET-Amplified Advanced Non-Small-Cell Lung Cancer

Number of pages: 40 Posted: 20 Jan 2020
Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Beijing Cancer Hospital, Nanjing Medical University - Department of Oncology, Fudan University, Harbin Medical University - Cancer Hospital, Guangzhou Medical University - First Affiliated Hospital, Jilin University (JLU) - First Affiliated Hospital, Government of the People's Republic of China - 307th Hospital, Central South University - Hunan Cancer Hospital, Tongji University - Shanghai Pulmonary Hospital, Soochow University - First Affiliated Hospital, AstraZeneca Pharmaceuticals - United States, AstraZeneca Pharmaceuticals - United States, AstraZeneca Pharmaceuticals - United Kingdom, AstraZeneca Pharmaceuticals - United Kingdom, AstraZeneca Pharmaceuticals - United Kingdom, AstraZeneca Pharmaceuticals - United Kingdom, AstraZeneca Pharmaceuticals - United Kingdom, AstraZeneca Pharmaceuticals - China and Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute
Downloads 35 (555,217)

Abstract:

Loading...

Savolitinib; Gefitinib; EGFR-TKI; NSCLC; China; MET

3.

The Resistance Landscape of Abivertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, and Clinical Strategy to Overcome Resistance in EGFR T790M-Positive Non-Small Cell Lung Cancer

Number of pages: 37 Posted: 28 Jan 2019
Guangdong Academy of Medical Sciences, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences, Burning Rock Biotech, Burning Rock Biotech, Burning Rock Biotech, Burning Rock Biotech, Guangdong Academy of Medical Sciences, Guangdong Academy of Medical Sciences, Guangdong Academy of Medical Sciences, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences, ACEA Therapeutics Inc., ACEA Therapeutics Inc., ACEA Therapeutics Inc., Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute and Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute
Downloads 35 (555,217)

Abstract:

Loading...

Abivertinib, resistance, EGFR amplification

4.

Development and Validation of a Gene Mutation-Based Signature to Predict Response to PD-1 Inhibitors in Non-Squamous NSCLC: A Retrospective Multicohort Study

Number of pages: 38 Posted: 12 May 2019
Southern Medical University - Department of Radiation Oncology, Southern Medical University - Department of Radiation Oncology, Southern Medical University - Department of Radiation Oncology, Southern Medical University - Department of Radiation Oncology, Southern Medical University - Department of Radiation Oncology, Southern Medical University - Hepatology Unit, Saint Louis University - College for Public Health and Social Justice, Southern Medical University - Department of Radiation Oncology, Southern Medical University - Department of Radiation Oncology, Southern Medical University - Department of Radiation Oncology, Southern Medical University - Department of Radiation Oncology, Southern Medical University - Hepatology Unit, Southern Medical University - Department of Radiation Oncology, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute and Southern Medical University - Department of Radiation Oncology
Downloads 30 (582,876)

Abstract:

Loading...

gene mutation-based signature (GMS); non-squamous non-small cell lung cancer; PD-1/PD-L1; predictive; immunotherapy

5.

Wait-and-See Treatment Strategy and Genomic Alternations Associated with Progression in Lung Adenocarcinoma with Pleural Dissemination

Number of pages: 28 Posted: 09 May 2019
Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangzhou University of Chinese Medicine, Geneseeq Technology Inc., Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Geneseeq Technology Inc., Geneseeq Technology Inc. - Nanjing Geneseeq Technology Inc., Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Geneseeq Technology Inc. - Nanjing Geneseeq Technology Inc., Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute and Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute
Downloads 25 (614,364)

Abstract:

Loading...

Lung adenocarcinoma, pleural dissemination, wait-and-see, genome instability, progression

6.

Bevacizumab Plus Erlotinib in Chinese Patients with Untreated, EGFR-Mutated, Advanced NSCLC (ARTEMIS-CTONG1509): A Multicenter Phase 3 Study

Number of pages: 56 Posted: 19 Dec 2020
Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Jilin Provincial Tumor Hospital - Department of Thoracic Oncology, China Medical University - Department of Medical Oncology, Harbin Medical University - Cancer Hospital, Jilin University (JLU) - The Cancer Center, Central South University - Department of Medical Oncology, Nanjing Military General Hospital - Respiratory Medicine, China Medical University - Medical Oncology Department of Thoracic Cancer, Shanghai Jiao Tong University (SJTU) - Medical Oncology, Zhejiang University - Respiratory Medicine, Henan Cancer Hospital - Respiratory Medicine, Huazhong University of Science and Technology (Formerly Tongi Medical University) - Medical Oncology, Fujian Cancer Hospital - Medical Oncology, Nanjing Medical University - Department of Oncology and Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute
Downloads 22 (635,172)
Citation 1

Abstract:

Loading...

bevacizumab, EGFR mutation, epidermal growth factor inhibitor, erlotinib, non-small-cell lung cancer, vascular endothelial growth factor inhibitor

7.

A Modified Phase 1 Clinical Trial of Abivertinib (Ac0010), a Third-Generation EGFR Tyrosine Kinase Inhibitor, in Chinese Patients with EGFR-T790M-positive Non-Small Cell Lung Cancer

Number of pages: 29 Posted: 06 Dec 2018
Government of the People's Republic of China - 307th Hospital, Government of the People's Republic of China - 307th Hospital, Chinese Academy of Medical Sciences, Zhejiang University, Chinese Academy of Medical Sciences, Central South University, Peking University - Cancer Hospital and Institute, Jilin Provincial Cancer Hospital, Chinese Academy of Medical Sciences, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences, ACEA Pharmaceutical Research, ACEA Therapeutics Inc., ACEA Therapeutics Inc., ACEA Therapeutics Inc. and Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute
Downloads 17 (670,873)

Abstract:

Loading...

abivertinib; AC0010; EGFR; NSCLC; T790M; Phase 1

8.

Genomic Signature for Personalized Adjuvant Therapy in Resected EGFR-Mutant Stage II-III Non-Small Cell Lung Cancer: Results from Phase 3 ADJVANT/CTONG1104 Study

Number of pages: 30 Posted: 28 Oct 2020
Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Geneseeq Technology Inc. - Nanjing Geneseeq Technology Inc., Fudan University - Zhongshan Hospital, Zhejiang Cancer Hospital, Geneseeq Technology Inc. - Nanjing Geneseeq Technology Inc., Geneseeq Technology Inc. - Nanjing Geneseeq Technology Inc., Central South University - Hunan Cancer Hospital, Fujian Medical University - Union Hospital, Jilin Provincial Cancer Hospital, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Geneseeq Technology Inc. - Nanjing Geneseeq Technology Inc., Geneseeq Technology Inc. - Geneseeq Research Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute and Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute
Downloads 13 (701,293)

Abstract:

Loading...

Adjuvant therapy, EGFR, TKI, chemotherapy, non-small cell lung cancer

9.

Genomic Stability and Non-Exhausted Immune Phenotype in Indolent T4N0M0 (Diameter ≥7 cm) Non-Small Cell Lung Cancers

Number of pages: 33 Posted: 15 Sep 2021
Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Southern Medical University - Second School of Clinical Medicine, Geneplus-Beijing Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Geneplus-Beijing Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Geneplus-Beijing Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Geneplus-Beijing Institute, Geneplus-Beijing Co. Ltd., Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute and Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute
Downloads 7 (748,685)

Abstract:

Loading...

intra-tumoural heterogeneity, clonal structure, chromosomal instability, indolent tumour, non-small cell lung cancer